(Q37779684)

23 August 2017

1 reference

title

Emergence of promising therapies in diabetes mellitus (English)

1 reference

23 August 2017

Sindhu Akkati

1

1 reference

PubMed ID

20705952

23 August 2017

Kishore Gnana Sam

series ordinal

2

1 reference

PubMed ID

20705952

23 August 2017

Girish Tungha

series ordinal

3

1 reference

23 August 2017

12 August 2010

1 reference

The Journal of Clinical Pharmacology

23 August 2017

1 reference

23 August 2017

51

1 reference

23 August 2017

6

1 reference

23 August 2017

796-804

1 reference

Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities

23 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Race/ethnic issues in obesity and obesity-related comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

The physiological rationale for oral insulin administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Oral insulin: the rationale for this approach and current developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

A review of exenatide as adjunctive therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Potential of liraglutide in the treatment of patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Why diabetes patients are more prone to the development of colon cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

Inhibitors of type 2 sodium glucose co-transporters--a new strategy for diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270010376972

21 January 2018

Identifiers

DOI

10.1177/0091270010376972

1 reference

23 August 2017

1 reference

PubMed ID

20705952